AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05632458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
Study NCT05654012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hormonal assessment
Description: Blood samples will be collected for analyses of sex hormone levels
Study NCT05654012 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Migraine-related measures
Description: Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
Study NCT05654012 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neural assessments
Description: MRI and fMRI scans
Study NCT05654012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pubertal status
Description: Pubertal status will be assessed using the self-reported Physical Developmental Scale-
Study NCT05549544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
Study NCT04417049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG
Description: All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
Study NCT05977634 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bladder training
Description: Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
Study NCT05977634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder training
Description: Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
Study NCT05977634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
Study NCT04942002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]
Description: Retrobulbar injection performed by care provider
Study NCT04942002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Standard treatment + placebo
Description: Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
Study NCT04991948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYAD-101
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
Study NCT04991948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-FU, leucovorin and oxaliplatin
Study NCT04991948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
Study NCT06677372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body temperature measurement
Description: Comparative analysis of temperature between esophageal temperature and skin temperature
Study NCT06676800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi Gubiao pill
Description: Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
Study NCT06676800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yiqi Gubiao Pill placebo
Description: The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel. Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
Study NCT06677515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR training
Description: The different VR scenarios comprise the following learning goals: 1) Social cognition. Interpreting social situations, understanding others; 2) Social communication. Express oneself, being understood by others; 3) Social competence. Interacting with others The investigators will use an MSI Raider GE78HX with a GeForce RTX4080 12GB GPU, running Windows 11, Unreal Engine 5.4, and the Meta Quest Link app, with a Meta Quest Pro as a PCVR headset connected via a Meta Quest Link cable. The setup works 100% locally, and no Wi-Fi or internet connection is used on the head-mounted-display or PC. The VR program itself does not store any data and will discard all that has happened inside the program, when restarted.
Study NCT06676397 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Punction
Description: venous blood sampling
Study NCT06675539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: French version PAWSS
Description: French version of the Prediction of Alcohol Withdrawal Severity Scale
Study NCT04352270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AD printed educational materials
Description: Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
Study NCT04352270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD educational videos
Description: Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
Study NCT06245759 — intervention group
Intervention type: OTHER
Intervention: This was a retrospective study and no patient intervention was performed
Description: This was a retrospective study and no patient intervention was performed
Study NCT06219187 — intervention group
Intervention type: OTHER
Intervention: Questionnaire completion
Description: To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~* Demographics~* Disease data
Study NCT06070207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP group
Description: Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
Study NCT06070207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eTEP group
Description: Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
Study NCT05003570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study NCT05003570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study NCT06365814 — intervention group
Intervention type: OTHER
Intervention: enhanced recovery after surgery
Description: ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
Study NCT06365814 — intervention group
Intervention type: OTHER
Intervention: conventional perioperative management
Description: conventional perioperative management
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 40mg
Description: Participants receive 40mg ND-003 tablets once.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 40mg
Description: Participants receive placebo tablet matching to receive 40mg of ND-003.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 80mg
Description: Participants receive 80mg ND-003 tablets once.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 80mg
Description: Participants receive placebo tablet matching to receive 80mg of ND-003.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 160mg
Description: Participants receive 160mg ND-003 tablets once.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 160mg
Description: Participants receive placebo tablet matching to receive 160mg of ND-003.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 240mg
Description: Participants receive 240mg ND-003 tablets once.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 240mg
Description: Participants receive placebo tablet matching to receive 240mg of ND-003.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 300mg
Description: Participants receive 300mg ND-003 tablets once.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 300mg
Description: Participants receive placebo tablet matching to receive 300mg of ND-003.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ND003_Dose 1
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_placebo_Dose 1
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 1
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ND003_Dose 2
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_placebo_Dose 2
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 2
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ND003_Dose 3
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ placebo_Dose 3
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effect_Cohort 1
Description: Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Study NCT06360874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effect_Cohort 2
Description: Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Study NCT06371651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Dietary supplement containing creatine and guanidinoacetic acid
Study NCT06371651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert substance
Study NCT06048237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Ultrasound Imaging of the diaphragm
Description: In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications.
Study NCT05604469 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of skin microbiota
Description: Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
Study NCT05242653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure by a cotton swab
Description: All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
Study NCT05242653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stromal hydration with the balanced salt solution（BSS）
Description: All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
Study NCT04754802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B Nasal Spray
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Study NCT04754802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Study NCT04884061 — intervention group
Intervention type: OTHER
Intervention: NBI images and/or videos
Description: A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
Study NCT05048641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whatsapp reminder
Description: Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
Study NCT06330519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate injection
Description: Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
Study NCT06330519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,1,1,2 tetrafluoroethane
Description: EndoIce (1,1,1,2 tetrafluoroethane) applied on the buccal, lingual (3 s/surface), and occlusal surfaces (4 s) for a total of 10 s then standard IANB was administered
Study NCT06330519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoral soft tissue cryotherapy
Description: Small ice packs (wrapped in sterile gauze) placed intraorally in the mouth on the vestibular surface of the treated tooth for 5 minutes then standard IANB was administered
Study NCT04841330 — intervention group
Intervention type: DEVICE
Intervention: Securis™ Stabilization Device
Description: A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
Study NCT05767736 — intervention group
Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.
Study NCT05767736 — intervention group
Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.
Study NCT06406933 — intervention group
Intervention type: DRUG
Intervention: Carbomer Gel/Jelly
Description: The drug is for dry eye syndrome by providing temporary relief from discomfort and irritation.
Study NCT05767736 — intervention group
Intervention type: DRUG
Intervention: Disease-Modifying Therapies (DMTs)
Description: Administered as specified in the treatment arm.
Study NCT06009224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS perioperative management
Description: * Epidural analgesia~* Fluid balance~* Other items are the same as conventional
Study NCT06760429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Nerve Block Type II
Description: In the PECS II group,once the needle tip reached the fascial plane between the pectoralis minor and serratus anterior muscles and there was no blood aspiration, 15 mL of 0.375% ropivacaine was injected. Then the needle was withdrawn until the needle tip reached the fascial plane between the pectoralis major and pectoralis minor muscles, and another 15 mL of 0.375% ropivacaine was injected. After the nerve block was implemented, the area of sensory block was marked, and the spread of the local anesthetic was monitored by ultrasound. Alcohol swabs and pinprick tests were used to detect cold and pain sensations.
Study NCT06013605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise and Leg Straightening
Description: Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
Study NCT06013605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg Straightening
Description: Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: Intravenous infusion
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Orally by mouth
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: subcutaneous injection or Intravenous infusion
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: subcutaneous injection or Intravenous infusion
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: subcutaneous injection
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vindesine
Description: Intravenous infusion
Study NCT05949593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinlarebant
Description: 5 mg tablet taken orally once a day
Study NCT05949593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for tinlarebant 5 mg prepared similarly.
Study NCT05482022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shiley™ phonate speaking valve
Description: The device connects to the tracheostomy tube. Usually used to aid vocalization.
Study NCT05482022 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: no intervention
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Intravenous infusion
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Intravenous infusion
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous infusion or orally
Study NCT06361329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ASP
Description: subcutaneous injection